Picture of Precision Biosciences logo

DTIL — Precision Biosciences News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousSmall CapNeutral

Precision BioSciences Inc expected to post a loss of 79 cents a share - Earnings Preview

Precision BioSciences Inc <DTIL.OQ> expected to post a loss of 79 cents a share - Earnings Preview 
  • Precision BioSciences Inc DTIL.OQ DTIL.O is expected to show a rise in quarterly revenue when it reports results on August 6 for the period ending June 30 2026

  • The Durham North Carolina-based company is expected to report a 6,150.0% increase in revenue to $1.125 million from $18 thousand a year ago, according to the mean estimate from 4 analysts, based on LSEG data.

  • ​LSEG's mean analyst estimate for Precision BioSciences Inc is for a loss of 79 cents per share.

  • The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 5 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

  • The mean earnings estimate of analysts was unchanged in the last three months. ​

  • Wall Street's median 12-month price target for Precision BioSciences Inc is $20.00, about 183.3% above its last closing price of $7.06

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING

STARMINESMARTESTIMATE®

LSEG IBES ESTIMATE

ACTUAL

BEAT, MET, MISSED

SURPRISE %

Mar. 31 2026

-0.61

-0.65

-0.75

Missed

-14.5

Dec. 31 2026

-0.62

-0.53

1.05

Beat

296.3

Sep. 30 2025

-1.94

-1.34

-1.84

Missed

-37.3​

Jun. 30 2025

-1.65

-1.57

-2.13

Missed

-36

​​Mar. 31 2025

-1.86

-1.72

-2.21

Missed

-28.7

Dec. 31 2024

-1.96

-2.22

Missed

-13.1​

Sep. 30 2024

-2.23

-1.92

-2.25

Missed

-17

Jun. 30 2024

-1.68

-1.50

4.67

Beat

410.3

This summary was machine generated August 4 at 14:26 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Recent news on Precision Biosciences

See all news